News

It's been a challenging past three years for AbbVie ( ABBV 1.84%). The pharmaceutical leader lost U.S. patent exclusivity for ...
While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...
Non-profit alleges that Humira pricing displaced essential healthcare, violated EU competition law and breached human rights | Court notes ‘social significance’ of case—but this can’t translate into ...
Prescription volume for specialty medications, not price hikes, largely seems to be the main factor in the ongoing huge ...
GL-IL2-138 is a small molecule RNA agent that modulates natural IL-2, allowing for downregulating or upregulating the immune system to fight devastating ...
AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.
Yuflyma is now fully interchangeable with the reference product, Humira (adalimumab), across all marketed dosage forms and strengths.
Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ensuring plan sustainability.
Restarting Humira regained control for over half of the study participants, but not everybody. I do understand that these are powerful medicines with side effects.
AbbVie (NYSE: ABBV) is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's success has propelled AbbVie to great heights, its recent patent ...
Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
AbbVie (NYSE: ABBV) was among the pharma companies worst positioned for a patent cliff that has come and gone. However, ...